Acute Lung Injury Market: Global Industry Analysis and Forecast (2022-2027) Trends, Statistics, Dynamics, Segmentation by Injury Type, Therapy, End User, and Region

Acute Lung Injury Market was valued at US$ 0.53 Bn. in 2021. The Global Acute Lung Injury Market size is expected to grow at a CAGR of 4.06 % through the forecast period.

Acute Lung Injury Market Overview:

Acute lung injury is a disorder of acute inflammation that destroys the endothelium and epithelial barriers of the lungs. Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are forms of Respiratory Failure that have large morbidity and mortality. Recent advances are going on in studying more about the pathogenesis, and treatment for ALI, but more progress is required to decrease the morbidity and mortality. The incidences of ALI may depend upon the factors such as Age and associated clinical disorders. The incidence of acute lung injury across the United States (1764 per 100,000 people) appears to be higher than in Europe, Australia, and other developed countries (1734 per 100,000 people). Mortality in patients with acute respiratory distress syndrome ranges from 34 to 58%. ALI is a life-threatening disorder; novel therapies are required to develop for reducing the mortality rate. The existing Clinical disorder and Age are factors having a major impact on mortality. Sepsis has s mortality rate of 43% whereas Trauma has an 11%. A lower mortality rate (24%) was found in children with age 15-19, whereas the highest(i.e., 60%) was found in ages above 75yrs. ALI can cause due to sepsis, burns, radiation, inhalation of noxious fumes, and fat embolism. Acute lung injury includes symptoms such as shortness of breath, low blood pressure, confusion, and extreme tiredness. ALI can cause due to sepsis, burns, radiation, inhalation of noxious fumes, and fat embolism. It is having a significant impact on public health, with a high incidence rate across the world. For proper management of this injury, it requires the administration of rapid and goal-oriented therapy for preventing further complications. Acute Lung Injury Market To know about the Research Methodology :- Request Free Sample Report 2021 is considered as a base year to forecast the market from 2022 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. The past five years' trends are considered while forecasting the market through 2027. 2020 is a year of exception and analysis, especially with the impact of lockdown by region.

Acute Lung Injury Market Dynamics:

Market Drivers in Acute Lung Injury Market: 1. Growing Geriatric Population: Globally the geriatric population has increased to 16% of the total world population. It is highest in Japan which is 28%, China at 11% and the United States is having around 16% geriatric population. The prevalence of acute lung injury is highest in the geriatric population, so the growing geriatric population is a driving factor for the acute lung injury market. The mortality rate is highest in the geriatric population therefore it is life-threatening in the old age people. 2. Growing awareness about health diagnostics: In recent times the awareness about health is increasing among people also due to the technological advances and diagnostic advances in the medical field. It has become easier for people to get diagnosed with the diseases. The growing awareness about health diagnostics is having an important contribution to increasing the market growth. The health screening market is expected CAGR of 12.4% through forecasted period which indicates the growing awareness about the health 3. Increasing Prevalence of Acute Lung Injury: The major driving factor is the increase in the prevalence of acute lung injury. The incidence of lung infections in people has increased in recent years. Pollution can be one of the major reasons for increasing lung infections and lung disorders. During the Covid pandemic, respiratory disorders were at their peak as the coronavirus was directly infecting the respiratory system. The United States is having a higher incidence of lung injuries that is around 75,000 peoples lose their lives yearly due to lung injuries. Talking about in the Asian countries such as India, China, and Japan the incidences are rising, and they are the emerging markets for acute lung injuries. Market Challenges in Acute Lung Injury Market: The main challenges which are hampering the growth of the acute lung injury market are the higher cost of the drugs for the treatment and the lack of specific treatment for the diagnosis of the disease. The lower adoption rate of digital radiography is one of the important factors that is holding back the market growth. Developments in the Acute Lung Injury Market: The research for specific treatment for Acute Lung Injury is going on with an aim of reducing the mortality rate. Various new drugs are in the pipeline which are in their late clinical phases and will be available in the next few years for the patients. The clinical advancements which are going on will be the key factors for the market growth in the future.

Acute Lung Injury Market Segment Analysis:

Based on injury Type, the Acute Lung Injury Market is segmented into Direct Injury and Indirect injury. The direct Injury segment is having higher market share than Indirect Injury. The direct Injury segment will be dominating in the forecasted period. Around 55% of Lung Injuries causes due to Direct Injury and according to our study, this percentage will be a rise through the forecasted period. Acute Lung Injury MarketBased on the Therapy, the Acute Lung Injury Market is segmented into Therapy by Medication and Devices. The Medication is subdivided into pharmacotherapy, Fluid Management, and Inhaled Nitric Oxide. Devices are divided again into Mechanical ventilation and Adjunctive procedures devices. The Respiratory Tract Diseases devices are expected to have a CAGR of 8.5% through the forecasted period. The medication segment is dominating the devices segment as there are various therapies used as a supportive treatment for Acute Lung Injury. As various advancements are going on medications for the treatment of lung injury, the medication segment will be dominating the market through the forecasted period also. Pharmacotherapy is with higher market share in the therapy segment. Around 39% of patients are getting treated with Nitric Oxide treatment for ALI.

Acute Lung Injury Market Regional Insights:

The North American region dominated the market with a 37% share in 2021. The North American region is expected to witness significant growth at a CAGR of 4.8% through the forecast period. The increasing prevalence of the ALI is a major reason for dominating the market. The ongoing advances and research in the medical field for specific treatment of ALI are driving the market because most of the key players are situated in North America. North America and Europe are also having a high prevalence of Acute Lung Injury. In the U.S about. Out of total deaths in Europe and the U.S around 7.5% and 6.9% of deaths are due to respiratory diseases. Asia Pacific region is an emerging market in the ALI market, and it is due to the larger population and higher percentage of Geriatric population in China and Japan i.e., 16% and 28% respectively. The percentage of respiratory diseases is increased in India from 4.5% to 6.4% in recent years. Also, the increased awareness about health diagnostics is a major reason for higher market share. The rising Lung infections in the region and increasing demand for medical devices and medications for the treatment of patients are driving the market in this region. Asia Pacific region is having about 24% of the market share and is expected to grow with a CAGR of 5.2%. The objective of the report is to present a comprehensive analysis of the global Acute Lung Injury Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Acute Lung Injury Market dynamic, and structure by analyzing the market segments and projecting the Acute Lung Injury Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Acute Lung Injury Market make the report investor’s guide.

Acute Lung Injury Market Scope: Inquiry Before Buying

Acute Lung Injury Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US$ 0.53 Bn.
Forecast Period 2022 to 2027 CAGR: 4.06% Market Size in 2027: US$ 0.74 Bn.
Segments Covered: by Injury Type • Direct Injury • Indirect Injury
by Therapy • Medication o Pharmacotherapy o Fluid Management o Nitric Oxide Inhalation • Devices o Mechanical Ventilation o Adjunctive Procedure Devices
by End User • Hospitals • Clinics • Others

Acute Lung Injury Market by Region

• North America • Europe • The Asia Pacific • South America • The Middle East and Africa

Acute Lung Injury Market Key Players

• Altor BioScience • FirstString Research • GlaxoSmithKline • Forschung und Entwicklung • Commence Bio • CompleGen • Histocell S.L. • Stemedica Cell Technologies • Windtree Therapeutics • S-Evans Biosciences • KYORIN Pharmaceutical Co • Implicit Bioscience Ltd • Faron Pharmaceuticals Ltd. • Carolus Therapeutics Frequently Asked Questions: 1] What segments are covered in the Global Acute Lung Injury Market report? Ans. The segments covered in the Acute Lung Injury Market report are based on Injury Type, Therapy, and End User. 2] Which region is expected to hold the highest share in the Global Acute Lung Injury Market? Ans. The North American region is expected to hold the highest share in the Acute Lung Injury Market. 3] What is the market size of the Global Acute Lung Injury Market by 2027? Ans. The market size of the Acute Lung Injury Market by 2027 is expected to reach US$ 0.74 Bn. 4] What is the forecast period for the Global Acute Lung Injury Market? Ans. The forecast period for the Acute Lung Injury Market is 2022-2027. 5] What was the market size of the Global Acute Lung Injury Market in 2021? Ans. The market size of the Acute Lung Injury Market in 2021 was valued at US$ 0.53 Bn.
1. Global Acute Lung Injury Market Size: Research Methodology 2. Global Acute Lung Injury Market Size: Executive Summary 2.1. Market Overview and Definitions 2.1.1. Introduction to Global Acute Lung Injury Market Size 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Acute Lung Injury Market Size: Competitive Analysis 3.1. MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2. Consolidation in the Market 3.2.1 M&A by region 3.3. Key Developments by Companies 3.4. Market Drivers 3.5. Market Restraints 3.6. Market Opportunities 3.7. Market Challenges 3.8. Market Dynamics 3.9. PORTERS Five Forces Analysis 3.10. PESTLE 3.11. Regulatory Landscape by region • North America • Europe • The Asia Pacific • The Middle East and Africa • South America 3.12. COVID-19 Impact 4. Global Acute Lung Injury Market Size Segmentation 4.1. Global Acute Lung Injury Market Size, by Injury Type (2021-2027) • Direct Injury • Indirect Injury 4.2. Global Acute Lung Injury Market Size, by Therapy (2021-2027) • Medication • Devices 4.3. Global Acute Lung Injury Market Size, by End User (2021-2027) • Hospitals • Clinic 5. North America Acute Lung Injury Market (2021-2027) 5.1. North America Acute Lung Injury Market Size, by Injury Type (2021-2027) • Direct Injury • Indirect Injury 5.2. North America Acute Lung Injury Market Size, by Therapy (2021-2027) • Medication • Devices 5.3. North America Acute Lung Injury Market Size, by End User (2021-2027) • Hospitals • Clinic 5.4. North America Acute Lung Injury Market, by Country (2021-2027) • The United States • Canada • Mexico 6. European Acute Lung Injury Market (2021-2027) 6.1. European Acute Lung Injury Market, by Injury Type (2021-2027) 6.2. European Acute Lung Injury Market, by Therapy (2021-2027) 6.3. European Acute Lung Injury Market, by End User (2021-2027) 6.4. European Acute Lung Injury Market, by Country (2021-2027) • The UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Acute Lung Injury Market (2021-2027) 7.1. Asia Pacific Acute Lung Injury Market, by Injury Type (2021-2027) 7.2. Asia Pacific Acute Lung Injury Market, by Therapy (2021-2027) 7.3. Asia Pacific Acute Lung Injury Market, by End User (2021-2027) 7.4. Asia Pacific Acute Lung Injury Market, by Country (2021-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. The Middle East and Africa Acute Lung Injury Market (2021-2027) 8.1. The Middle East and Africa Acute Lung Injury Market, by Injury Type (2021-2027) 8.2. The Middle East and Africa Acute Lung Injury Market, by Therapy (2021-2027) 8.3. The Middle East and Africa Acute Lung Injury Market, by End User (2021-2027) 8.4. The Middle East and Africa Acute Lung Injury Market, by Country (2021-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Acute Lung Injury Market (2021-2027) 9.1. South America Acute Lung Injury Market, by Injury Type (2021-2027) 9.2. South America Acute Lung Injury Market, by Therapy (2021-2027) 9.3. South America Acute Lung Injury Market, by End User (2021-2027) 9.4. South America Acute Lung Injury Market, by Country (2021-2027) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1. GlaxoSmithKline 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Altor BioScience 10.3. FirstString Research 10.4. Forschung und Entwicklung 10.5. Commence Bio 10.6. CompleGen 10.7. Histocell S.L. 10.8. Stemedica Cell Technologies 10.9. Windtree Therapeutics 10.10. S-Evans Biosciences 10.11. KYORIN Pharmaceutical Co 10.12. Implicit Bioscience Ltd 10.13. Faron Pharmaceuticals Ltd. 10.14. Carolus Therapeutics

About This Report

Report ID 146138
Category Healthcare
Published Date May 2022
Updated Date
Contact Us